Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Sechter

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Current Pharmaceutical Design|February 3, 2007
Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphismP Vandel, J M Talon, E Haffen, et al.
L'Encephale|July 1, 1994
[Action and tolerance of dothiepin hydrochloride (Prothiaden) in depressive states during the evolution of psychotic disorders]D Sechter, R De Sahb, A Boudet, et al.
L'Encephale|August 6, 1999
[Clinical tolerance of a new antidepressant -- milnacipran]W Regina, P Vandel, S Vandel, et al.
La Revue Du Praticien|April 15, 1996
[Neurotic syndrome: obsessive neurosis. Diagnosis, treatment]J Boiteux, N Gandelet, B Bonin, et al.
Therapie|March 1, 1992
Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?P Bonnet, S Vandel, S Nezelof, et al.
Therapie|July 8, 1999
Serotonin syndrome after sertraline, buspirone and loxapine?B Bonin, P Vandel, S Vandel, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 1, 1997
Tricyclic antidepressant-induced extrapyramidal side effectsP Vandel, B Bonin, E Leveque, et al.
L'Encephale|February 11, 2000
[Abuse of tianeptine. A case report]P Vandel, W Regina, B Bonin, et al.
L'Encephale|December 1, 1991
[Prediction of suicide risk]D Sechter, B Bonin, G Bertschy, et al.
Medical Hypotheses|December 1, 1996
CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effectsP Vandel, B Bonin, S Vandel, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Current Pharmaceutical Design|February 3, 2007
Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphismP Vandel, J M Talon, E Haffen, et al.
L'Encephale|July 1, 1994
[Action and tolerance of dothiepin hydrochloride (Prothiaden) in depressive states during the evolution of psychotic disorders]D Sechter, R De Sahb, A Boudet, et al.
L'Encephale|August 6, 1999
[Clinical tolerance of a new antidepressant -- milnacipran]W Regina, P Vandel, S Vandel, et al.
La Revue Du Praticien|April 15, 1996
[Neurotic syndrome: obsessive neurosis. Diagnosis, treatment]J Boiteux, N Gandelet, B Bonin, et al.
Therapie|March 1, 1992
Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?P Bonnet, S Vandel, S Nezelof, et al.
Therapie|July 8, 1999
Serotonin syndrome after sertraline, buspirone and loxapine?B Bonin, P Vandel, S Vandel, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 1, 1997
Tricyclic antidepressant-induced extrapyramidal side effectsP Vandel, B Bonin, E Leveque, et al.
L'Encephale|February 11, 2000
[Abuse of tianeptine. A case report]P Vandel, W Regina, B Bonin, et al.
L'Encephale|December 1, 1991
[Prediction of suicide risk]D Sechter, B Bonin, G Bertschy, et al.
Medical Hypotheses|December 1, 1996
CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effectsP Vandel, B Bonin, S Vandel, et al.
Pageof 9